舒泰神(300204)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300204 舒泰神

已收盘 06-12 15:00:00

{"stockData":{"symbol":"300204","market":"SZ","secType":"STK","nameCN":"舒泰神","latestPrice":21.05,"timestamp":1781247804000,"preClose":20.38,"halted":0,"volume":26919527,"delay":0,"changeRate":0.0329,"floatShares":454000000,"shares":478000000,"eps":-0.1756,"marketStatus":"已收盘","change":0.67,"latestTime":"06-12 15:00:00","open":20.39,"high":21.35,"low":19.82,"amount":556000000,"amplitude":0.0751,"askPrice":21.05,"askSize":157,"bidPrice":21.04,"bidSize":111,"shortable":0,"etf":0,"ttmEps":-0.1756,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781487000000},"marketStatusCode":5,"adr":0,"adjPreClose":20.38,"symbolType":"stock","openAndCloseTimeList":[[1781227800000,1781235000000],[1781240400000,1781247600000]],"highLimit":22.42,"lowLimit":18.34,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":477772555,"isCdr":false,"pbRate":12.02,"roa":"--","roe":"--","epsLYR":-0.16,"committee":-0.641194,"marketValue":10057000000,"turnoverRate":0.0593,"status":0,"floatMarketCap":9550000000},"requestUrl":"/m/hq/s/300204/wiki","defaultTab":"wiki","newsList":[{"id":"2642407219","title":"6月11日舒泰神跌6.81%，景顺长城医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642407219","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642407219?lang=zh_cn&edition=full","pubTime":"2026-06-11 16:32","pubTimestamp":1781166759,"startTime":"0","endTime":"0","summary":"证券之星消息，6月11日舒泰神跌6.81%创60日新低，收盘报20.38元，换手率6.08%，成交量27.59万手，成交额5.71亿元。重仓舒泰神的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为景顺长城基金的景顺长城医疗健康混合A。景顺长城医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100025674.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300204","BK0239","159760","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642426109","title":"舒泰神：子公司博佳凝获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2642426109","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642426109?lang=zh_cn&edition=full","pubTime":"2026-06-10 20:48","pubTimestamp":1781095697,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神06月09日在投资者关系平台上答复投资者关心的问题。舒泰神（北京）生物制药股份有限公司子公司江苏贝捷泰生物科技有限公司于2026年06月09日收到了国家药品监督管理局核准签发的注射用STSP-0601《药品注册证书》，取得了该药品生产的注册批件。相关事项您可查阅公司于2026年06月09日在巨潮资讯网披露的《关于子公司药品博佳凝获得药品注册证书的公告》。感谢您对公司的关注，谢谢！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000039789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300204","BK0239","BK0046","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642173465","title":"舒泰神最新公告：子公司药品博佳凝获国家药监局注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2642173465","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642173465?lang=zh_cn&edition=full","pubTime":"2026-06-09 17:13","pubTimestamp":1780996428,"startTime":"0","endTime":"0","summary":"舒泰神(300204.SZ)公告称，公司子公司江苏贝捷泰生物科技有限公司收到国家药监局核准签发的注射用波米泰酶α(商品名：博佳凝)《药品注册证书》，该药品为治疗用生物制品1类，适用于凝血因子VIII或IX的抑制物＞5个Bethesda单位的先天性血友病A或B成人患者的出血治疗。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900027940.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","300204","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641100838","title":"6月8日舒泰神跌5.04%，景顺长城医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641100838","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641100838?lang=zh_cn&edition=full","pubTime":"2026-06-08 16:57","pubTimestamp":1780909074,"startTime":"0","endTime":"0","summary":"证券之星消息，6月8日舒泰神跌5.04%，收盘报23.57元，换手率5.18%，成交量23.5万手，成交额5.68亿元。重仓舒泰神的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为景顺长城基金的景顺长城医疗健康混合A。景顺长城医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800022551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300204","BK0028","159760","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639233936","title":"5月29日舒泰神涨9.28%，景顺长城医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2639233936","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639233936?lang=zh_cn&edition=full","pubTime":"2026-05-29 16:54","pubTimestamp":1780044866,"startTime":"0","endTime":"0","summary":"证券之星消息，5月29日舒泰神涨9.28%，收盘报25.78元，换手率13.28%，成交量60.23万手，成交额15.63亿元。重仓舒泰神的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为景顺长城基金的景顺长城医疗健康混合A。景顺长城医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900030637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","159760","BK0046","300204"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636848859","title":"舒泰神（300204）发布2025年年度股东会决议公告，5月20日股价下跌0.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636848859","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636848859?lang=zh_cn&edition=full","pubTime":"2026-05-20 17:35","pubTimestamp":1779269732,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，舒泰神报收于26.58元，较前一交易日下跌0.34%，最新总市值为126.99亿元。该股当日开盘26.55元，最高27.0元，最低26.23元，成交额达3.34亿元，换手率为2.77%。近日，舒泰神（北京）生物制药股份有限公司发布《2025年年度股东会决议公告》。会议表决结果均获高比例同意，中小投资者参与表决并单独计票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000033813.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300204","BK0239","BK0028","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636267990","title":"舒泰神最新公告：向特定对象发行股票获证监会同意注册批复","url":"https://stock-news.laohu8.com/highlight/detail?id=2636267990","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636267990?lang=zh_cn&edition=full","pubTime":"2026-05-18 17:19","pubTimestamp":1779095970,"startTime":"0","endTime":"0","summary":"舒泰神(300204.SZ)公告称，公司收到证监会出具的批复，同意公司向特定对象发行股票的注册申请。本次发行应严格按照报送深交所的申报文件和发行方案实施，批复自同意注册之日起12个月内有效。公司董事会将按规定办理相关事宜并及时履行信息披露义务。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800024776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300204","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635745250","title":"舒泰神（300204）披露召开2025年年度股东会提示性公告，5月14日股价下跌1.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635745250","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635745250?lang=zh_cn&edition=full","pubTime":"2026-05-14 22:24","pubTimestamp":1778768656,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘，舒泰神报收于27.65元，较前一交易日下跌1.88%，最新总市值为132.1亿元。该股当日开盘28.18元，最高28.9元，最低27.6元，成交额达5.94亿元，换手率为4.67%。舒泰神（北京）生物制药股份有限公司于2026年5月14日发布《关于召开2025年年度股东会的提示性公告》。公告显示，公司定于2026年5月19日召开2025年年度股东会，会议采取现场表决与网络投票相结合的方式。股权登记日为2026年5月11日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400043008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0046","300204"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633019591","title":"舒泰神：聘任李世诚先生担任公司副总经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2633019591","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633019591?lang=zh_cn&edition=full","pubTime":"2026-05-08 08:42","pubTimestamp":1778200933,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神05月07日在投资者关系平台上答复投资者关心的问题。公司于2025年03月23日召开第六届董事会第六次会议，审议通过了《关于公司聘任高级管理人员的议案》，聘任李世诚先生担任公司副总经理、白雪莲女士担任公司临床研究中心总经理、王静峰先生担任公司营销自营事业部总经理、张蕾女士担任公司人力资源总监、田磊先生担任公司生产中心总监。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800007594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0239","300204"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632467425","title":"每周股票复盘：舒泰神（300204）2025年亏损收窄但2026Q1净利下滑261%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632467425","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632467425?lang=zh_cn&edition=full","pubTime":"2026-05-03 03:19","pubTimestamp":1777749550,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，舒泰神报收于27.63元，较上周的28.07元下跌1.57%。本周，舒泰神4月28日盘中最高价报29.17元。本周关注点来自业绩披露要点：舒泰神2025年归母净利润-7776.33万元，同比上升46.31%。股本股东变化截至2026年3月31日，公司股东户数为8.27万户，较2025年12月31日增加1.9万户，增幅29.94%。2025年研发投入占营收比例达70.81%。预计2026年度与关联方发生日常关联交易总额不超过12,682.22万元。公司将于2026年5月20日举行2025年度业绩网上说明会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300000644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0239","300204"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631637027","title":"舒泰神：继续推进注射用STSP-0601附条件批准上市工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2631637027","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631637027?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:48","pubTimestamp":1777553294,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神(300204)04月29日在投资者关系平台上答复投资者关心的问题。投资者提问：公司的0601迟迟没批复，是否存在被否的可能性？如果被否，公司怎么维持日常现金流？舒泰神回复：您好！公司前期已按照发补通知要求组织相关部门落实并补充提交了相关材料，继续推进注射用STSP-0601附条件批准上市工作。有关研发项目进展，敬请关注CDE平台公示、后续定期报告及项目进展公告。如您希望对公司进行更多了解，欢迎您致电公司投资者热线（010-67875255），谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000065831.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300204","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631555280","title":"舒泰神（300204）2026年一季报简析：净利润同比下降261.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631555280","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631555280?lang=zh_cn&edition=full","pubTime":"2026-04-29 09:07","pubTimestamp":1777424869,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期舒泰神发布2026年一季报。根据财报显示，舒泰神净利润同比下降261.1%。截至本报告期末，公司营业总收入4689.77万元，同比下降25.81%，归母净利润-843.18万元，同比下降261.1%。本次财报公布的各项数据指标表现不尽如人意。生意拆解：公司过去三年净经营资产收益率分别为--/--/--，净经营利润分别为-3.99亿/-1.48亿/-8810.52万元，净经营资产分别为3.71亿/3.28亿/3.31亿元。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202604/29/20260429852813.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202604/29/20260429852813.png"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260429/32187662.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300204"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630292397","title":"舒泰神（300204）披露2025年年度股东会通知，4月27日股价下跌2.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630292397","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630292397?lang=zh_cn&edition=full","pubTime":"2026-04-27 22:03","pubTimestamp":1777298587,"startTime":"0","endTime":"0","summary":"截至2026年4月27日收盘，舒泰神报收于27.51元，较前一交易日下跌2.0%，最新总市值为131.44亿元。近日，舒泰神（北京）生物制药股份有限公司发布《关于召开2025年年度股东会的通知》。公告显示，公司将于2026年05月19日召开2025年年度股东会，会议采取现场表决与网络投票相结合的方式，股权登记日为2026年05月11日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700045323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300204","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630836420","title":"图解舒泰神一季报：第一季度单季净利润同比下降261.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630836420","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630836420?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:52","pubTimestamp":1777283536,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神2026年一季报显示，一季度公司主营收入4689.77万元，同比下降25.81%；归母净利润-843.18万元，同比下降261.1%；扣非净利润-906.29万元，同比下降168.39%；负债率37.94%，投资收益19.12万元，财务费用351.11万元，毛利率78.19%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700032976.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300204"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629471860","title":"奥克股份：公司与北京舒泰神建立合作关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2629471860","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629471860?lang=zh_cn&edition=full","pubTime":"2026-04-24 09:09","pubTimestamp":1776992950,"startTime":"0","endTime":"0","summary":"证券之星消息，奥克股份(300082)04月23日在投资者关系平台上答复投资者关心的问题。投资者提问：舒泰神3350聚乙二醇原料来自公司吗？奥克股份回复：尊敬的投资者，您好！公司与北京舒泰神建立合作关系（在定期报告中已有披露）。公司严格遵守相关法律法规及商业保密原则，相关信息如涉及信息披露要求，公司将在定期报告或临时公告中及时予以披露。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400025593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0046","300204","BK0201","BK0239","300082","BK0028","BK0155","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628745447","title":"舒泰神最新公告：聚乙二醇3350散获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2628745447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628745447?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:14","pubTimestamp":1776676444,"startTime":"0","endTime":"0","summary":"舒泰神(300204.SZ)公告称，公司近日收到国家药监局核准签发的聚乙二醇3350散《药品注册证书》。该药品为化学药品3类，适应症为缓解偶发性便秘，上市许可持有人及生产企业均为舒泰神。此次获证标志着公司取得了该药品在国内市场生产、销售的资格，有助于进一步丰富公司产品管线，提升相关产品的市场竞争力。鉴于医药产品受市场环境、销售渠道等因素影响，上市后销售情况存在不确定性，敬请投资者注意投资风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000023369.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0046","300204"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625436941","title":"舒泰神：继续推进注射用STSP-0601附条件批准上市工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2625436941","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625436941?lang=zh_cn&edition=full","pubTime":"2026-04-08 20:51","pubTimestamp":1775652681,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神04月07日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，贵公司用于治疗血友病的独家创新药 STSP-0601 上市申请已获受理，并被纳入优先审评，预计 2026年 有望获批上市。公司前期已按照发补通知要求组织相关部门落实并补充提交了相关材料，继续推进注射用STSP-0601附条件批准上市工作。公司重视BD工作的开展，并有相应人员进行推动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040800036391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300204","BK0239","BK0028","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624213668","title":"舒泰神（300204）披露向特定对象发行股票募集说明书（注册稿），4月3日股价下跌4.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624213668","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624213668?lang=zh_cn&edition=full","pubTime":"2026-04-03 22:04","pubTimestamp":1775225063,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，舒泰神报收于31.52元，较前一交易日下跌4.28%，最新总市值为150.59亿元。该股当日开盘31.14元，最高33.19元，最低31.14元，成交额达21.3亿元，换手率为14.66%。近日，舒泰神（北京）生物制药股份有限公司披露《2025年度向特定对象发行股票募集说明书（注册稿）》。公告显示，公司拟向特定对象发行股票，募集资金总额不超过12.53亿元，用于创新药物研发项目及补充流动资金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300043105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300204","BK0239","BK0028","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624465853","title":"舒泰神：公司暂无研发方向相关合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2624465853","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624465853?lang=zh_cn&edition=full","pubTime":"2026-04-03 15:00","pubTimestamp":1775199644,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神(300204)04月02日在投资者关系平台上答复投资者关心的问题。投资者提问：1. 药石科技在分子砌块、连续流工艺、ADC/TPD关键中间体等领域具备国内独一档的技术壁垒，也是很多创新药公司早期研发和CMC开发的重要合作伙伴。请问贵司在管线研发中，是否与药石科技有合作？未来是否有计划在早期化合物发现、工艺开发或商业化生产层面开展合作？舒泰神回复：您好！公司暂无研发方向相关合作。感谢您对公司的关注，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300023603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300204","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624566325","title":"舒泰神不超12.53亿定增获深交所通过 国金证券建功","url":"https://stock-news.laohu8.com/highlight/detail?id=2624566325","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624566325?lang=zh_cn&edition=full","pubTime":"2026-04-01 11:42","pubTimestamp":1775014922,"startTime":"0","endTime":"0","summary":"中国经济网北京4月1日讯 舒泰神 昨晚披露关于收到《关于舒泰神(北京)生物制药股份有限公司申请向特定对象发行股票的审核中心意见告知函》的公告称，舒泰神于2026年03月31日收到深圳证券交易所上市审核中心出具的《关于舒泰神(北京)生物制药股份有限公司申请向特定对象发行股票的审核中心意见告知函》。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202604/01/20260401991506.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202604/01/20260401991506.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260401/32117880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","BK0201","300204","600109","BK0183","BK0188","BK0276","BK0028","BK0012","BK0046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1781454587663,"stockEarnings":[{"period":"1week","weight":-0.1519},{"period":"1month","weight":-0.253},{"period":"3month","weight":-0.1742},{"period":"6month","weight":-0.2287},{"period":"1year","weight":-0.3899},{"period":"ytd","weight":-0.2295}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0497},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0366},{"period":"1year","weight":0.1848},{"period":"ytd","weight":0.0158}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"舒泰神(北京)生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"82652人(较上一季度增加29.94%)","perCapita":"5488股","listingDate":"2011-04-15","address":"北京市大兴区北京经济技术开发区经海二路36号","registeredCapital":"47777万元","survey":"　　舒泰神(北京)生物制药股份有限公司的主营业务是生物药物的研发、生产和营销。公司的主要产品是苏肽生、舒泰清。公司是国家级高新技术企业。","listedPrice":52.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"舒泰神(300204)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供舒泰神(300204)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"舒泰神,300204,舒泰神股票,舒泰神股票老虎,舒泰神股票老虎国际,舒泰神行情,舒泰神股票行情,舒泰神股价,舒泰神股市,舒泰神股票价格,舒泰神股票交易,舒泰神股票购买,舒泰神股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"舒泰神(300204)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供舒泰神(300204)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}